Nefecon and Ambrisentan in IgA Nephropathy

This study is testing a combination of two drugs — nefecon (a targeted gut-released steroid) and ambrisentan (a drug that widens blood vessels) — for people with IgA nephropathy, a kidney disease caused by immune deposits that damage the kidneys over time. **You may be eligible if:** - You are between 18 and 70 years old - You have been diagnosed with IgA nephropathy by kidney biopsy within the past 4 years - You have significant protein in your urine (at least 0.5 g per 24 hours) - Your kidney filtration rate (eGFR) is at least 30 mL/min/1.73 m² **You may NOT be eligible if:** - Your biopsy shows special subtypes of kidney disease that look similar to IgA nephropathy but are a different condition - You have secondary IgA nephropathy caused by another disease (such as lupus, hepatitis, or rheumatoid arthritis) - You are pregnant or breastfeeding - You have severe kidney disease or uncontrolled blood pressure Talk to your doctor to see if this trial is right for you.